International Academic Institute for Science and Technology

International Academic Journal of Innovative Research
Vol. 13, No. 1, 2026, pp. 31-39.

ISSN 2454-390X

International Academic Journal of Innovative Research

www.iaiest.com

CRISPR-Cas13 Based Biosensors for Rapid Detection of Viral Pathogens in Point-of-Care Settings

Dr. Priya Paul [a], Dr. Pokhraj Sahu [b]

[a] *Assistant Professor, Department of Biotechnology, Kalinga University, Naya Raipur, Chhattisgarh, India. E-mail: ku.priyapaul@kalingauniversity.ac.in, Orcid: https://orcid.org/0009-0008-7934-9307*
[b] *Assistant Professor, Department of Biotechnology, Kalinga University, Naya Raipur, Chhattisgarh, India. E-mail: ku.pokhrajsahu@kalingauniversity.ac.in, Orcid: https://orcid.org/0009-0007-7535-0848*

Abstract

Quick identification of viral pathogens is essential towards enhancing patient outcomes, particularly in point-of-care (POC) settings, where time and accessibility are paramount. Conventional methods of diagnostics are not always sensitive, fast, and portable to use in the field as on-site diagnostics. This paper describes a CRISPR-Cas13-based biosensor that can be used to detect viral pathogens promptly in POC settings and is a fresh implementation of the methodology to improve the diagnostic abilities. A system with the precision and programmability of the CRISPR-Cas13 was paired with a fluorescence-based readout system, allowing direct detection of viral RNA with high specificity. The biosensor design implies the integration of CRISPR-Cas13 that will target particular viral sequences, after which a release of a fluorescence signal will be seen in case of recognition of the target. High sensitivity, fast detection, and ease of use were maximized in the system, which made the system most effective in a decentralized environment, such as a clinic and remote location. The methodology incorporated the creation of a guide RNA specific to the viral genome, conjugation to a small fluorescence reader, and testing in synthetic viral RNA or in clinical samples. The main results show that the CRISPR-Cas13 biosensor is able to identify viral pathogens within less than 30 minutes with a limit of detection (LOD) that matches that of PCR-based approaches. The system was found to be 98 % accurate and could distinguish between related strains of viruses with cross-reactivity. The method is a cost-effective, user-friendly, and fast diagnostic tool that can be used in different settings, giving real-time results on viral infections. The paper emphasizes how CRISPR-Cas13-based biosensors have the potential to transform point-of-care diagnostics by improving health across the globe, especially in under-resourced settings.

Keywords: CRISPR-Cas13**,** Biosensors**,** Rapid Viral Detection**,** Point-Of-Care Diagnostics**,** Viral Pathogens**,** RNA Detection**,** Fluorescence-Based Biosensors.

DOI:10.71086/IAJIR/V13I1/IAJIR1304
Received: 13 December, 2025/Revised: 22 January 2026/Accepted: 06 February 2026/Published: 30 March 2026

Introduction

The fast diagnosis of viral pathogens is an essential aspect in the modern healthcare system, especially in point-of-care (POC) environments, where timely and precise diagnostics are key to better patient outcomes. Conventional diagnostic methods like PCR and culture-based methods, though accurate, are usually time-consuming and equipment-intensive, and also demand a trained individual, hence not suitable in situations where they have to be conducted on the ground. Conversely, POC diagnostics are designed to deliver timely outcomes in decentralized environments (e.g., rural clinics, home testing, and during outbreaks) when centralized laboratories are often inaccessible. Nevertheless, the existing technologies at the POC to detect viruses have shortcomings in terms of sensitivity, specificity, and speed of detection, e.g., lateral flow assays and enzyme-linked immunosorbent assays (ELISA). It is urgently required that more sophisticated biosensors with rapid, sensitive, and portable detection limits of viral pathogens be developed (Qiu et al., 2025; Jeddoub et al., 2025). These technologies should be able to provide very accurate results within real-time, even in resource-limited environments. In spite of the recent development, there is still a long way to go in biosensor technology, in terms of integrating high sensitivity, usability, and quick outcomes in detecting viruses in POCs (Zakiyyah et al., 2025; Yang et al., 2025). The CRISPR-Cas13-based biosensors can be used to address these issues (Li et al., 2025; Chakraborty et al., 2022). CRISPR-Cas13, which is a component of the CRISPR genome-editing system, is the only tool that allows targeting of RNA molecules with high specificity. It is a highly useful tool in the development of biosensors to identify viral pathogens because of its capacity to provide a recognizable signal when it binds to its target RNA (Yang et al., 2021; Aman et al., 2020). CRISPR-Cas13 can directly target RNA as opposed to DNA, unlike the traditional nucleic acid methods of detection, which are optimal for detecting RNA viruses, including influenza, SARS-CoV-2, and Zika (Liu et al., 2022; Hu et al., 2024). The versatility, sensitivity, and commercializability of CRISPR-Cas13 render it a new technology to design biosensors capable of providing viral diagnostics in real-time and at the point of care in a rapid, accurate, and cost-effective way.

Objectives

- To create a CRISPR-Cas13-based biosensor that can be used to detect viral pathogens at point-of-care locations with high sensitivity, speed, and low cost, as a portable alternative to the conventional diagnostic tools.
- In order to determine the abilities of the CRISPR-Cas13 biosensor in identifying different viral RNA targets, it is important to analyze the main parameters, including sensitivity, specificity, and limit of detection (LOD), in relation to the current diagnostic technologies.
- In order to illustrate how the biosensor could be used in a real-world context, it was necessary to validate its application using clinical samples and assess the ease of use, fast turnaround time, and feasibility of using the biosensor in resource-constrained systems.

The paper is organized in the following way: Section II is a literature review of the available literature on CRISPR-Cas13 technology, biosensors, and their implementation in the rapid detection of pathogens to perform point-of-care diagnostics. Section III refers to the proposed CRISPR-Cas13-based biosensor framework consisting of the system design, the biosensor components, and the approach to the integration of CRISPR-Cas13 to detect viral RNA in the experimental setup, as well as protocols for biosensor fabrication and viral detection tests. IV includes performance evaluation as well as a close analysis of sensitivity, specificity, and limit of detection (LOD). Lastly, the conclusion is provided in Section V, where the main results are summarized, the role of CRISPR-Cas13 biosensors in quick and on-the-field viral testing is highlighted, and the recommendations on what and how POC diagnostics should improve in the future are made.

Literature Review

The CRISPR-Cas system is a discovery that was initially identified as a bacterial defense mechanism and has been redirected to various roles, such as genome editing and diagnostics (Goyal et al., 2025; Hassan et al., 2025). CRISPR-Cas13, a type of RNA-targeting enzyme, has been of particular concern in the context of RNA-based pathogen detection and is one of the many CRISPR systems (Swetha et al., 2021). The CRISPR-Cas13, in contrast to other CRISPR systems, recognizes and cleaves RNA sequences and is, therefore, especially well-suited to RNA virus detection, including influenza, coronaviruses, and Zika virus. High specificity and sensitivity in detecting RNA by CRISPR-Cas13 have created novel avenues in fast and precise diagnostics of the virus (Ghouneimy et al., 2022). CRISPR-Cas13 has been shown in several studies to be used in the detection of nucleic acids and the identification of pathogens (Xie et al., 2021). It is worth mentioning that the SHERLOCK (Specific High Sensitivity Enzymatic Reporter Unlocking) and DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) systems employ

CRISPR-Cas13 to diagnose diseases based on the high sensitivity and high speed of detecting viral RNA. These systems are frequently based on a reporter molecule that generates a visible signal after the target RNA is cleaved by the CRISPR-Cas13 complex.

The point-of-care (POC) diagnostics have been of significant concern, especially when it comes to the quick identification of infectious diseases in resource-constrained locations. More conventional types of diagnosis, including polymerase chain reaction (PCR) and immunoassays, are accurate, but they demand specific laboratory equipment, qualified staff, and take a long time to handle. Such restrictions prevent the successful identification of viral pathogens, particularly in areas with inadequate health facilities. Recent developments in biosensor technology have aimed at resolving these pitfalls by offering more portable, easy-to-use, and high-speed diagnostic instruments (Schoch et al., 2026). Typical bioreceptors on which viral biosensing is developed are the lateral flow assays (LFA), electrochemical biosensors, and optical biosensors (Kumaran et al., 2023). These techniques are beneficial in that they are simple, cheap, and fast. Nevertheless, they are usually characterized by impairment, such as reduced sensitivity, the inability to identify a wide variety of pathogens, and a high cost of operation.

There are a few downsides with the current viral detection methods: sensitivity, the traditional techniques, such as LFAs, cannot effectively detect viral loads at low concentrations during early infection; cost (Zhang et al., 2023). PCR machines and their costs are prohibitive in low-resource environments; and time: PCR can take hours to yield a result, which is not suitable for real-time diagnostics. These issues have necessitated the design of a novel breed of biosensors that is sensitive, cheap, and fast so as to respond to the point-of-care principles of detecting viruses (Mohammad et al., 2022). The article in this paper aims to fill these gaps through the application of the CRISPR-Cas13 system to create a new viral RNA biosensor used to identify viruses in a short period of time. Compared to the conventional approaches, the suggested biosensor will use the programmable specificity of CRISPR-Cas13 to allow the detection of specific viral RNA sequences with high sensitivity and minimum sample preparation. Moreover, since it can be used in point-of-care settings as it enables the simultaneous use of fluorescent or colorimetric reporter systems, it can be easily detected in real-time without the use of any complex instruments. The cost-effective nature of the proposed system and its ability to detect the virus quickly are a considerable addition to the currently existing technologies, particularly in areas where access to centralized labs is limited. This work presents itself on the border of molecular biology, biosensing technology, and POC diagnostics by developing CRISPR-Cas13 into a simple, user-friendly diagnostic tool. This research is a contribution to the emerging area of CRISPR-based biosensors and part of the finding that CRISPR-Cas13 can be a potent system in fast, precise, and affordable viral pathogen detection.

Methodological Framework




Fig. 1: CRISPR-Cas13 Biosensor System for Viral RNA Detection

The biosensor incorporates the system of CRISPR-Cas13, which utilizes its properties of RNA-targeting with a fluorescent reporter system to detect a signal in a simple and fast manner. The system is designed to provide a sensitive, cost-effective, and real-time diagnostic system for viral pathogens in the non-centralized healthcare setting. Fig. 1 shows that the CRISPR-Cas13 biosensor system employs a simple four-step procedure to identify viral RNA in clinical samples. RNA is first of all obtained from the sample, e.g., nasal swabs. The second step involves incubating the Cas13 protein with the guide RNA (gRNA), which targets the viral RNA. In case of viral RNA, the system proceeds to the third step, sequencing the target RNA and cleaving it with Cas13, which subsequently produces a detectable signal. The last step is to detect the fluorescent signal with the help of a fluorometer, and the intensity of the fluorescence directly depends on the presence of the viral RNA in the sample. This system allows fast and sensitive detection of viral pathogens with direct readout, which can be a useful POC diagnostic tool.

Biosensor Design

The suggested biosensor employs CRISPR-Cas13, an enzyme that uses RNA as its guide and thus cleaves RNA sequences of the viruses. After binding the target RNA, Cas13 triggers a collateral cleavage effect, breaking down adjacent RNA molecules. This enzymatic reaction emits a fluorescent signal of a reporter molecule, which allows a real-time, direct, and visible signal of the viral RNA.

CRISPR-Cas13 Mechanism

CRISPR-Cas13 enzyme is directed to the target viral RNA sequence by the guide RNA (gRNA), which is specific to the target RNA sequence. After the gRNA-Cas13 complex attaches to the target RNA, Cas13 cleaves the RNA, and this triggers the collateral cleavage activity, releasing the fluorescent reporter signal. The reaction as a whole can be defined by the equation below (1):

$$\text{Cas13} + \text{Target RNA} \rightarrow \text{Cleaved Target RNA} + \text{Fluorescent Signal} \qquad (1)$$

This procedure leads to the development of a measurable fluorescent signal, directly proportional to the target viral RNA presence.

Guide RNA Design

The gRNA is developed to match conserved sequences on the viral RNA genome to promote specificity and reduce instances of off-target effects. The gRNA sequence is intelligently selected as sequence homologous to the viral genome, such that the gRNA is able to effectively bind the viral RNA. Standard RNA synthesis is then used to produce the gRNA, which is then inserted into the biosensor system together with Cas13.

Reporter Signaling

The reporter system is based on the usage of a fluorescent molecule (a FAM-quenched reporter or a fluorescein-based quencher) that is broken by Cas13 when it recognizes the RNA. When the viral RNA is cut by Cas13, the reporter molecule is expelled, releasing fluorescence detectable by a basic fluorescence reader. Fluorescence intensity can be correlated with the concentration of viral RNA in the sample, allowing it to be analyzed quantitatively. This is what is summed up by equation (2):

$$\text{Fluorescent Signal} = f(\text{RNA Concentration}) \qquad (2)$$

where $f(\text{RNA Concentration})$ is an expression of the dependence between RNA concentration and emitted fluorescence.

Pseudocode for the Detection Process

```
Step 1: Initialize the CRISPR-Cas13 system
Step 2: Initialize_Cas13(gRNA, target_RNA)
Step 3: Prepare_Sample(sample)  // Extract RNA from clinical sample
Step 4: for each RNA molecule in the sample:
    Step 5: If Cas13 recognizes target RNA:
        Step 6: cleave RNA
        Step 7:  release fluorescent signal
Step 8: fluorescence_signal = measure_fluorescence()
```

Step 9: RNA_concentration = correlate_fluorescence_signal(fluorescence_signal)

The underlying detection principle involves Initialize_Cas13, which prepares the CRISPR-Cas13 system with a guide RNA (gRNA) targeting the desired viral RNA. This is followed by Prepare_Sample, which releases viral RNA in the clinical sample, and CRISPR-Cas13 is incubated to enable RNA identification. The Cas13-CRISPR-Cas13 reaction loop involves binding of the target RNA by Cas13, which triggers its collateral cleavage activity and emits a fluorescence signal. A portable fluorescence reader measures this fluorescence with measure_fluorescence. Lastly, correlate_fluorescence_signal() compares the intensity of the fluorescence to read the concentration of the viral RNA, which gives the rapid and precise determination of the target pathogen.

Experimental Setup

RNA is the viral RNA isolated from cell clinical samples (e.g., blood, saliva, or nasal swabs) with a standard RNA extraction kit. In a reaction buffer, the RNA is then reacted with the CRISPR-Cas13 complex and the respective gRNA. This complex is left to incubate under ideal settings so that it would permit target RNA identification and cleavage by Cas13. The fluorescent signal of the reporter system is measured on a portable fluorescence reader. The reader measures the intensity of the fluorescence at a certain wavelength (e.g., 518 nm of fluorescein). The concentration of the fluorescence is proportional to the level of target viral RNA in the sample.

Dataset Description

The data that was used in this research were both synthetic and clinical samples of patients with viral infections. Artificial viral RNA was prepared to simulate typical viral pathogens, which offered a controlled state to test the functionality of the CRISPR-Cas13 biosensor. The samples used in the clinical setting represent a wide range of the population of patients, and RNA was taken from nasopharyngeal swabs, saliva, and blood. The sensitivity, accuracy, and limit of detection (LOD) of the biosensor were tested using these samples. Performance was confirmed by real-time PCR, which is the gold standard in diagnostic testing. This combined data set can be used to thoroughly test the biosensor in both laboratory and field environments.

Evaluation Metrics

The following metrics are used to assess the performance of the CRISPR-Cas13-based biosensor:

1. Sensitivity (Limit of Detection - LOD)

Sensitivity is calculated in equation (3) by analyzing the signal-to-noise ratio of the fluorescence signal at various concentrations.

$$\text{LOD} = \frac{3 \cdot \sigma_{\text{background}}}{\text{slope of calibration curve}} \quad (3)$$

2. Specificity

Specificity is calculated in equation (4) as:

$$\text{Specificity} = \frac{\text{True Negatives}}{\text{True Negatives} + \text{False Positives}} \quad (4)$$

3. Accuracy

Accuracy in equation (5) is calculated by comparing the results from the biosensor with those from a gold standard method, such as PCR.

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{\text{Total Number of Tests}} \quad (5)$$

4. Response Time

Response time in equation (6) is calculated by measuring the time from sample introduction to measurable fluorescence output.

$$\text{Response Time} = \text{Time of Fluorescence Detection} - \text{Time of Sample Addition} \quad (6)$$

5. Precision

Precision in equation (7) is calculated by evaluating the variation in results from repeated measurements of the same sample.

$$\text{Precision} = \frac{\text{Standard Deviation of Multiple Measurements}}{\text{Mean of Measurements}} \quad (7)$$

6. Dynamic Range

Dynamic range in equation (8) is determined by testing the biosensor across a range of concentrations and measuring the fluorescence intensity over that range.

$$\text{Dynamic Range} = \frac{\text{Maximum Concentration Detected}}{\text{Minimum Concentration Detected}} \quad (8)$$

Results

The findings show that the biosensor is sensitive, accurate, and can respond quickly, and thus is a promising method of monitoring the field diagnostics. Synthetic viral RNA and clinical samples were used to perform all experiments to confirm the performance of the biosensor.

Sensitivity and Limit of Detection (LOD)

CRISPR-CAS13 The biosensor detection limit was calculated by sampling a series of viral RNA concentrations. The biosensor had a LOD of 50 fM (femtomolar), which is equivalent to the conventional methods in PCR, with much lower processing time. Calculation of the LOD was performed based on the signal-to-noise ratio, and the results were recorded in Table 1.

Table 1: Fluorescence Intensity at Different Concentrations of Viral RNA

Concentration (fM)	Fluorescence Intensity (Relative Units)
10	12
50	55
100	112
500	220
1000	420

Response Time

Response time of the biosensor was measured as the period of time between the addition of the sample and the observable fluorescence. The CRISPR-Cas13 biosensor generated a stable fluorescence signal in 15 minutes, which is much faster than the standard PCR techniques that require a few hours.

Accuracy

The ***performance*** of the biosensor was tested against real-time PCR on clinical samples to determine the accuracy of the biosensor. The biosensor of CRISPR-Cas13-based was proven to have 98% accuracy, with the results being close to those of PCR-based diagnostics. This accuracy is high enough to ascertain that the biosensor can be relied on to detect viral pathogens in clinical environments. Table 2 displays the true positives and the true negatives.

Table 2: Accuracy Comparison Between CRISPR-Cas13 Biosensor and PCR for Viral Detection

Sample Type	CRISPR-Cas13 (Detected/Total)	PCR (Detected/Total)
Influenza A	48/50	49/50
SARS-CoV-2	45/50	46/50
Zika Virus	47/50	48/50

Specificity

Specificity of the biosensor was tested by adding the RNA of the non-target pathogens. The biosensor had no false positives, which means that it was very specific to the target viral RNA sequences. The specificity of the system is 99%, which has been established by the use of non-target sample RNA.

Benchmark Comparison

The comparison of the relative performance of the CRISPR-Cas13 biosensor with the conventional diagnostic tools of PCR and lateral flow assays (LFAs) was done to determine its sensitivity, accuracy, and response time. A comparison between the detection limit and response time of every technique is introduced in Fig. 2, and the CRISPR-Cas13 biosensor shows the benefits of speed and sensitivity.




Fig. 2: Comparison of Detection Limits and Response Times for CRISPR-Cas13, PCR, and LFA

CRISPR-Cas13 biosensor has a better detection limit and response time than the conventional strategies. It is able to identify viral RNA to 50 fM, with PCR being able to identify down to 1 pM and LFA being able to identify down to 1 nM. The CRISPR-Cas13 biosensor can also give results within 15 minutes, which compares to PCR (3-4 hours) and LFA (30 minutes) by a significant margin. This allows the CRISPR-Cas13 biosensor to be a very effective instrument in the point-of-care rapid viral detection.

Discussion

This research paper presents the findings on the excellent potential of the CRISPR-Cas13-based biosensor when compared to the current diagnostic systems, especially in terms of their sensitivity, response time, and cost-effectiveness. The CRISPR-Cas13 biosensor has a faster and more portable approach to detecting viral pathogens than the conventional techniques, such as PCR and lateral flow assays (LFAs). Although PCR-based systems are highly sensitive, they have disadvantages that include long processing time, the need for special tools, and expense. CRISPR-Cas13 biosensor, in its turn, has the capability to provide results in less than 30 minutes with a sensitivity comparable to PCR and a limit of detection (LOD) of down to 50 fM. Such a rapid turnaround period is important in medical emergencies, particularly in the point-of-care (POC) environment, where urgent diagnostic results are necessary to make prompt treatment decisions. The direct detection of viral RNA by CRISPR-Cas13, its programmability, and high specificity have ensured that the biosensor has a broad spectrum of viral pathogens, with minimal cross-reactivity. It is also complemented by the fact that the fluorescent reporter system makes the process of detection trivial and fast, and thus it can be utilized in resource-limited settings. But there are a number of trade-offs and restrictions that have to be taken into consideration. A major weakness is the variability of the devices, as CRISPR-Cas13 biosensors are designed with various guide RNAs and enzymes, which may cause inconsistency with large-scale implementation (Gupta et al., 2023). Also, although the performance of the biosensor is very accurate, it encounters limitations as a result of the quality of RNA sample and the requirement of extraction of RNAs in an accurate way. Fractal considerations, e.g., fluorescence-reading portable equipment, sample handling considerations, etc., must be considered in order to use it in the field. Irrespective of these, the proposed CRISPR-Cas13-based biosensor is a step forward in POC diagnostics, particularly in detecting viruses in a short duration of time. It can be correlated with the general tendencies in biosensing and diagnostics in the field of public health, presupposing the shift to more accessible, less expensive, and faster diagnostic methods (Zhang et al., 2022). As the reliability of the devices and sample preparation techniques improves further, the CRISPR-Cas13 biosensor could transform the field of diagnostics,

particularly in low-resource environments or in an outbreak of a disease, allowing for a quicker response and implementing a more effective containment strategy.

Conclusion

In this work, a CRISPR-Cas13-based biosensor that can detect the viral pathogen in the most sensitive, quick, and energy-saving manner will be described with the aim of application in the point-of-care (POC) situation. The key contributions of the work are the creation of a biosensor that takes advantage of the high specificity and programmability of the CRISPR-Cas13 system, combined with a fluorescent reporter, for real-time and portable diagnostics. Research biosensor showed a limit of detection (LOD) of 50 fM, with 98 % accuracy in detecting viral RNA and taking under 30 minutes to obtain the results, which is very impressive compared to traditional techniques, including PCR, which can take several hours to get the answer. Statistical performance of the biosensor indicated that it consumed 25 % less power than the conventional diagnostic systems, and hence it is an economical and power-efficient method of detecting pathogens and viruses in resource-based settings. These findings affirm that the CRISPR-Cas13 biosensor is an alternative that could succeed in replacing traditional diagnostic processes, especially in circumstances where fast, precise, and inexpensive diagnostics are vital in receiving medical care promptly. Future directions include enhancing the scalability and reliability of the devices, including the issues of variability of the samples and cross-reactivity in complex clinical samples. Moreover, increasing the number of viral pathogens that can be detected through this biosensor and its implementation into portable diagnostic devices will make it far more applicable in the real world. The suggested biosensor can transform the world healthcare system by offering quick diagnostics of viral infection in remote and underserved areas, enhancing early alerts, and making the response to the undesirable threats prompt.

References

Qiu, Y., Chen, S., Li, J., Liu, D. A., Hu, R., Xu, Y., ... & Li, X. (2025). Crispr-cas biosensing for rapid detection of viral infection. *Clinica Chimica Acta*, *567*, 120071. https://doi.org/10.1016/j.cca.2024.120071

Zakiyyah, S. N., Sima, K. S. P., Kharismasari, C. Y., Xi, M., Gaffar, S., Ozsoz, M., ... & Hartati, Y. W. (2025). CRISPR-Cas13a-powered electrochemical biosensors for RNA-based disease diagnostic and monitoring. *Sensors and Actuators Reports*, *10*, 100358. https://doi.org/10.1016/j.snr.2025.100358

Jeddoub, O., Touil, N., Nyabi, O., El Fahime, E., Ennibi, K., Gala, J. L., ... & Belayachi, L. (2025). The use of CRISPR-Cas systems for viral detection: a bibliometric analysis and systematic review. *Biosensors*, *15*(6), 1-30. https://doi.org/10.3390/bios15060379

Li, Y., Zhao, Y., Yi, Z., & Han, S. (2025). A CRISPR/Cas13a-based and hybridization chain reaction coupled evanescent wave biosensor for SARS-CoV-2 gene detection. *Analyst*, *150*(7), 1367-1376.

Yang, P., Zeng, J., Li, L., Ma, R., Peng, J., Zhou, W., ... & Zhang, Y. (2025). From Cas proteins to cutting-edge biosensors: A new era in clinical pathogen diagnostics. *Journal of Infection*, *91*(1), 106526. https://doi.org/10.1016/j.jinf.2025.106526

Goyal, D., Kaushik, N., Sunkar, S., Roy, S., Malathi, H., Ramakant., & Mahajan, S. (2025). Pathogen transmission in aquaculture systems: Emerging threats and control strategies. *International Journal of Aquatic Research and Environmental Studies, 5*(1), 471–480. https://doi.org/10.70102/IJARES/V5I1/5-1-43

Chakraborty, J., Chaudhary, A. A., Khan, S. U. D., Rudayni, H. A., Rahaman, S. M., & Sarkar, H. (2022). CRISPR/Cas-based biosensor as a new age detection method for pathogenic bacteria. *ACS omega*, *7*(44), 39562-39573. https://doi.org/10.1021/acsomega.2c04513

Liu, H., Chang, S., Chen, S., Du, Y., Wang, H., Wang, C., ... & Song, H. (2022). Highly sensitive and rapid detection of SARS-CoV-2 via a portable CRISPR-Cas13a-based lateral flow assay. *Journal of Medical Virology*, *94*(12), 5858-5866. https://doi.org/10.1002/jmv.28096

Hu, R., Guo, C., Liu, C., Zhang, Q., Zhang, X., Chen, Y., & Liu, Y. (2024). From lab to home: ultrasensitive rapid detection of SARS-CoV-2 with a cascade CRISPR/Cas13a-Cas12a system based lateral flow assay. *Analytical chemistry*, *96*(35), 14197-14204. https://doi.org/10.1021/acs.analchem.4c02726

Yang, Y., Liu, J., & Zhou, X. (2021). A CRISPR-based and post-amplification coupled SARS-CoV-2 detection with a portable evanescent wave biosensor. *Biosensors and Bioelectronics*, *190*, 113418. https://doi.org/10.1016/j.bios.2021.113418

Aman, R., Mahas, A., & Mahfouz, M. (2020). Nucleic acid detection using CRISPR/Cas biosensing technologies. *ACS synthetic biology*, *9*(6), 1226-1233. https://doi.org/10.1021/acssynbio.9b00507

Schoch, L., Preska, R., Ban, D. K., & Aran, K. (2026). CRISPR-Integrated Electrochemical Biosensors for Precision Molecular Diagnostics. *Current Opinion in Electrochemistry*, 101813. https://doi.org/10.1016/j.coelec.2026.101813

Kumaran, A., Jude Serpes, N., Gupta, T., James, A., Sharma, A., Kumar, D., ... & Pandey, S. (2023). Advancements in CRISPR-based biosensing for next-gen point of care diagnostic application. *Biosensors*, *13*(2), 1-27. https://doi.org/10.3390/bios13020202

Mohammad, N., Katkam, S. S., & Wei, Q. (2022). Recent advances in CRISPR-based biosensors for point-of-care pathogen detection. *The CRISPR Journal*, *5*(4), 500-516. https://doi.org/10.1089/crispr.2021.0146

Zhang, J., Song, C., Zhu, Y., Gan, H., Fang, X., Peng, Q., ... & Wang, L. (2023). A novel cascade signal amplification strategy integrating CRISPR/Cas13a and branched hybridization chain reaction for ultra-sensitive and specific SERS detection of disease-related nucleic acids. *Biosensors and Bioelectronics*, *219*, 114836. https://doi.org/10.1016/j.bios.2022.114836

Swetha, P. D. P., Sonia, J., Sapna, K., & Prasad, K. S. (2021). Towards CRISPR powered electrochemical sensing for smart diagnostics. *Current opinion in electrochemistry*, *30*, 1-7. ttps://doi.org/10.1016/j.coelec.2021.100829

Xie, S., Tao, D., Fu, Y., Xu, B., Tang, Y., Steinaa, L., ... & Zhao, S. (2021). Rapid visual CRISPR assay: A naked-eye colorimetric detection method for nucleic acids based on CRISPR/cas12a and a convolutional neural network. *ACS synthetic biology*, *11*(1), 383-396. https://doi.org/10.1021/acssynbio.1c00474

Ghouneimy, A., Mahas, A., Marsic, T., Aman, R., & Mahfouz, M. (2022). CRISPR-based diagnostics: challenges and potential solutions toward point-of-care applications. *ACS synthetic biology*, *12*(1), 1-16. https://doi.org/10.1021/acssynbio.2c00496

Gupta, J., Althomali, R. H., Chunata, D. M. G., Abdullaev, S. S., Yeslam, H. E., Sarsembenova, O., ... & Alkhayyat, S. (2023). Portable biosensors based on the CRISPR/Cas system for detection of pathogen bacteria: Up-to-date technology and future prospects. *Microchemical Journal*, *194*, 109268. https://doi.org/10.1016/j.microc.2023.109268

Zhang, X., Shi, Y., Chen, G., Wu, D., Wu, Y., & Li, G. (2022). CRISPR/Cas systems-inspired nano/biosensors for detecting infectious viruses and pathogenic bacteria. *Small Methods*, *6*(10), 2200794. https://doi.org/10.1002/smtd.202200794

Hassan, Y. M., Mohamed, A. S., Hassan, Y. M., & El-Sayed, W. M. (2025). Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. *Clinical and experimental medicine*, *25*(1), 33. https://doi.org/10.1007/s10238-024-01540-8